Royal Bank of Canada Reiterates Outperform Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They presently have a $11.00 price objective on the biotechnology company’s stock, up from their prior price objective of $10.00. Royal Bank of Canada’s price objective would […]
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They presently have a $11.00 price objective on the biotechnology company’s stock, up from their prior price objective of $10.00. Royal Bank of Canada’s price objective would […]
